Background
==========

The Krüppel-like factor (*KLF*) proteins belong to a family of transcription factors that bind to GC-GT rich sites and CACC boxes of a large range of gene promoters \[[@B1]-[@B4]\]. Binding of these factors is mediated by a highly conserved DNA-binding motif of C2H2 zinc fingers localised at their C-terminus \[[@B5]\], which suggests that these proteins could have a redundant activity. However, accumulated evidence shows that each *KLF*has its own function and regulation \[[@B6],[@B7]\]. *KLF*transcription factors act as transcriptional activators or repressors depending on the specificity of promoters to which they bind and the cellular context. Moreover, they interact with various co-activators or co-repressors, regulating via different mechanisms, the transcription of their target genes \[[@B4]\].

We recently identified both rare and frequent genetic variants in KLF11 co-segregating with early onset familial diabetes or associated with late-onset T2D \[[@B8]\]. These results prompted us to assess the putative genetic contribution to T2D risk of additional *KLF*family members, especially those presumably involved in energy and glucose homeostasis, through their expression in the pancreas, adipose tissue, liver and muscle \[[@B9]-[@B11]\]. Indeed, KLF2, *KLF5*, and *KLF6*have been suggested to be involved in adipocyte differentiation \[[@B12]-[@B14]\]; KLF2 and *KLF15*may contribute to adipogenesis transcriptional regulation via PPARγ signalling \[[@B15],[@B16]\]. In particular, this implication in the differentiation process of adipocytes, suggests they may play an important role in insulin resistance, a status prone to T2D development.

Thus, the possible implication of the *KLF*family in glucose homeostasis and adipogenesis makes its members relevant gene candidates for T2D. Therefore, we assessed if frequent genetic variants in several members of the *KLF*family are implicated in genetic susceptibility to T2D development in a French population. To assess the putative contribution of genetic variability of KLFs gene family members to type 2 diabetes (T2D) we performed a two-stage association study.

Methods
=======

Subjects
--------

Normoglycemic and type 2 diabetic subjects were defined according to World Health Organization criteria. The characteristics of the first case-control study, summarized in table [1](#T1){ref-type="table"}, included 365 French T2D unrelated patients with at least one affected first-degree relative (D1) and 363 non diabetic, unrelated spouses from T2D families (C1) recruited by the \"Centre National de la Recherche Scientifique\"-Institute Pasteur Unit in Lille. The second sample set (table [1](#T1){ref-type="table"}) included 750 T2D patients (D2) recruited at the Endocrinology-Diabetology Department of the Corbeil-Essonne Hospital, and 741 control individuals (C2) from the D.E.S.I.R. study (Données Epidemiologiques sur le Syndrome d\'Insulino-Resistance \[[@B17]\]).

###### 

General characteristics of the French populations studied

                                                    **Case-control Set 1**   **Case-Control Set 2**                
  ------------------------------------------------- ------------------------ ------------------------ ------------ ------------
  Numbers studied                                   365                      363                      750          741
  Sex (men/women)                                   196/169                  136/227                  455/295      294/447
  Age at examination (years, mean ± SD)             \-                       59 ± 13                  \-           53 ± 6
  Age at diagnosis of diabetes (years, mean ± SD)   45 ± 11                  \-                       48 ± 10      \-
  BMI (kg/m^2^, mean ± SD)                          26.8 ± 3.8               25.4 ± 4.7               33.0 ± 6.4   23.0 ± 1.8

SNP screening and genotyping
----------------------------

Single nucleotide polymorphisms (SNPs) in putative linkage disequilibrium blocks of the *KLF3*, *KLF4*, *KLF5, KLF6, KLF12*, and *KLF13*genes were chosen from available Taqman^®^assays (SNP browser 3.0) and genotyped by Taqman^®^SNP Genotyping Assay (Applied Biosystems, Foster City, CA, U.S.A.). For *KLF*15 and *KLF*16 genes, no Taqman^®^probes were available from the SNP Browser 3.0. We screened the *KLF*2, *KLF*15 and *KLF*16 genes for variants by direct sequencing of the promoter region (up to 1 kb), the 5\' and 3\' UTRs, exons and flanking intron sequences of the genes in DNA samples from 32 unrelated individuals using the ABI Prism 377 DNA sequencer. The identified SNPs were genotyped by Light Cycler/Lightyper technology (Roche Diagnostic, Basel, Switzerland). SNPs were genotyped in the first case-control set and those with a minor allele frequency over 10% (MAF\>10%) that showed a trend to be associated with T2D (P \< 0.10) were further studied in the second case-control set. Duplicate measurements were included to validate the genotype scores with 100% of concordance.

Statistical analysis
--------------------

SNPs of several *KLF*family members were genotyped in the first case-control set of 728 individuals. Comparison of allelic frequencies between cases and controls used a χ2 test with the Pearson P-value under an allelic model (FINETTI program \[[@B18]\]). The Odds Ratios (ORs) with 95% confidence intervals (CIs) for allelic effects were calculated with the same program. In the first set, D1/C1, the statistical power, calculated with the PAWE program \[[@B19]\] to detect an OR of 1.4, was 68% to 84% (α = 0.05, minor allele frequency (MAF) = 0.15 to 0.20). To increase the power, we selected SNPs with a significance level of P \< 0.10 for further analysis (power = 78% to 90%). The power to detect an OR of 1.29, previously reported for KLF11 \[[@B8]\], is 57% to 65% in this set (MAF = 0.15 to 0.20). We genotyped the selected SNPs in the set D2/C2 of 1,491 individuals. The power of the overall study (D/C) with 2,219 individuals was 99% for an OR = 1.4 (α = 0.05, MAF = 0.15) and over 84% for the observed ORs (0.75--1.27) of the selected SNPs in first set D1/C1.

Results
=======

In the first case-control set, we genotyped 28 frequent variants of 9 different members of the KLF gene family with a minor allele frequency (MAF) above 0.10 (table [2](#T2){ref-type="table"}). All SNPs were in Hardy-Weinberg equilibrium according to the FINETTI program (data not shown). In table [2](#T2){ref-type="table"}, we present the NCBI reference number (dbSNP ID) and details for each SNP genotyped, as well as the MAF and the P-value under an allelic model. From this first study set (D1/C1), three SNPs showed an association with T2D; *KLF2*rs12459387 (P = 0.09, MAF = 0.12, OR = 0.75 with 95% CI = 0.53--1.05), *KLF4*rs10759240 (P = 0.08, MAF = 0.52, OR = 0.83 with 95% CI = 0.67--1.02) and *KLF*5 rs11841945 (P = 0.04, MAF = 0.40, OR = 1.27 with 95% CI = 1.02--1.59).

###### 

Genotypic distribution of KLF SNPs in type 2 diabetic and non-diabetic individuals

  **dbSNP ID**              **N/M**               **MAF D1/C1**         **P-value**            **MAF D2/C2**          **P-value**            **MAF D/C**            **P-value**
  ------------------------- --------------------- --------------------- ---------------------- ---------------------- ---------------------- ---------------------- -------------
  **KLF2, Chr. 19q13**      0.31 (167, 142, 34)   0.69                                                                                                              
  Prom -789                 C/T                   0.32 (148, 143, 30)                                                                                               
  rs10424657                G/A                   0.30 (175, 146, 34)   0.61                                                                                        
                                                  0.31 (162, 155, 32)                                                                                               
  rs12459387                C/T                   0.09 (292, 58, 4)     0.09                   0.10 (464, 106, 6)     0.87                   0.10 (756, 164, 10)    0.40
                                                  0.12 (260, 78, 2)                            0.10 (543, 123, 6)                            0.11 (803, 201, 8)     
  rs7248864                 C/T                   0.09 (295, 56, 5)     0.13                                                                                        
                                                  0.12 (270, 78, 2)                                                                                                 
  rs3745318                 C/T                   0.21 (211, 109, 16)   0.67                                                                                        
                                                  0.20 (214, 114, 11)                                                                                               
  rs12462380                A/G                   0.41 (119, 178, 56)   0.24                                                                                        
                                                  0.44 (102, 170, 63)                                                                                               
  rs7258799                 A/T                   0.13 (277, 81, 6)     0.15                                                                                        
                                                  0.16 (219, 74, 10)                                                                                                
  rs15336                   C/A                   0.19 (235, 111, 12)   0.21                                                                                        
                                                  0.16 (235, 94, 8)                                                                                                 
  rs11086029                A/T                   0.22 (209, 121, 14)   0.63                                                                                        
                                                  0.21 (217, 117, 13)                                                                                               
                                                                                                                                                                    
  **KLF3, Chr. 4q14**       0.44 (110, 180, 70)   0.89                                                                                                              
  rs2045767                 G/T                   0.45 (105, 182, 68)                                                                                               
  rs9522                    C/T                   0.45 (110, 171, 75)   0.62                                                                                        
                                                  0.46 (97, 178, 72)                                                                                                
                                                                                                                                                                    
  **KLF4, Chr. 9q31**       0.47 (97, 174, 79)    0.08                  0.49 (144, 297, 133)   0.68                   0.48 (241, 471, 212)   0.08                   
  rs10759240                C/A                   0.52 (80, 168, 95)                           0.51 (176, 361, 187)                          0.51 (256, 529, 282)   
                                                                                                                                                                    
  **KLF5, Chr. 13q21**      0.16 (248, 97, 6)     0.67                                                                                                              
  rs12428414                C/T                   0.16 (237, 88, 11)                                                                                                
  rs4885065                 A/G                   0.17 (245, 94, 11)    0.83                                                                                        
                                                  0.16 (247, 98, 8)                                                                                                 
  rs9564944                 A/G                   0.12 (263, 69, 5)     0.90                                                                                        
                                                  0.12 (269, 62, 8)                                                                                                 
  rs11841945                C/G                   0.46 (94, 173, 65)    0.04                   0.42 (200, 271, 110)   0.20                   0.43 (294, 444, 175)   0.91
                                                  0.40 (110, 145, 48)                          0.45 (227, 349, 151)                          0.43 (337, 494, 199)   
                                                                                                                                                                    
  **KLF6, Chr. 10p15**      0.11 (290, 68, 5)     0.63                                                                                                              
  rs7005                    C/T                   0.12 (281, 66, 8)                                                                                                 
                                                                                                                                                                    
  **KLF12, Chr. 13q21**     0.36 (148, 164, 47)   0.36                                                                                                              
  rs1927010                 A/T                   0.32 (154, 162, 38)                                                                                               
  rs4885151                 G/T                   0.31 (165, 166, 31)   0.80                                                                                        
                                                  0.32 (169, 144, 42)                                                                                               
  rs7993625                 C/T                   0.24 (205, 128, 21)   0.60                                                                                        
                                                  0.23 (199, 133, 12)                                                                                               
  rs6650443                 A/G                   0.19 (245, 99, 19)    0.66                                                                                        
                                                  0.20 (224, 107, 15)                                                                                               
  rs9600167                 C/G                   0.35 (154, 158, 46)   0.49                                                                                        
                                                  0.23 (160, 141, 44)                                                                                               
                                                                                                                                                                    
  **KLF13, Chr. 15q12**     0.44 (120, 169, 74)   0.71                                                                                                              
  rs11855557                A/G                   0.45 (102, 189, 64)                                                                                               
  rs12592176                G/A                   0.50 (84, 186, 83)    0.49                                                                                        
                                                  0.48 (98, 172, 84)                                                                                                
  rs4779516                 T/C                   0.44 (115, 175, 70)   0.36                                                                                        
                                                  0.46 (96, 187, 69)                                                                                                
                                                                                                                                                                    
  **KLF15, Chr. 3q13**      0.12 (268, 74, 4)     0.35                                                                                                              
  3\'UTR+244del(CACGAAGG)   0.10 (285, 58, 7)                                                                                                                       
                                                                                                                                                                    
  **KLF16, Chr. 19q13**     0.47 (100, 162, 79)   0.11                                                                                                              
  rs11670146                A/G                   0.47 (101, 144, 56)                                                                                               
  rs3746045                 T/C                   0.24 (208, 120, 24)   0.23                                                                                        
                                                  0.21 (214, 119, 14)                                                                                               

D, type 2 diabetic patients; C, non-diabetic individuals; MAF, minor allele frequency; (number of subjects with wild type homozygote; heterozygote; mutant homozygote alleles); P-value for differences between allele frequencies under an allelic model.

In the second case-control set, we genotyped *KLF2*rs12459387, *KLF4*rs10759240 and *KLF5*rs11841945, but the observed difference in MAF between cases and controls in D1/C1 was not confirmed (Table [2](#T2){ref-type="table"}). In fact, the trend for allelic association with T2D observed in the first set was not replicated for these SNPs in the second set (D2/C2), nor were they significant after the combined analysis of both groups (D/C). As D2 had a higher mean body mass index (BMI) compared to D1, we also analyzed the data of individuals with BMI \< 27 kg/m^2^but still no significant difference was observed. In addition, we did not observe associations between these three SNPs and quantitative traits such as fasting insulin, fasting glucose, OGTT.

Since our study is probably limited by the fact that it does not cover all the genetic variability of the KLF genes, we analysed additional SNPs included in our recently published genome wide association study \[[@B20]\]. The SNPs located in regions spanning the KLF genes, and analyzed in this genome wide association study (148) showed no significant association with T2D in this French population (data not shown).

Discussion
==========

We have analysed SNPs within nine KLF genes and we were not able to show a genetic T2D association in our population. A similar study in a Japanese population also showed no evidence for an association with other variants of the same *KLF*genes analysed in our study (*KLF2*, -3, -5, -12, -13 and *KLF16*\[[@B21]\]). However, it is worth noting that some *KLF*genes are not covered extensively with HapMap genotyped SNPs. In fact, this was the case for *KLF*15 and *KLF*16 gene regions, where at the start of this study no Taqman^®^assays were available. Therefore, we decided to screen these genes for common SNPs. Since we analysed in our study all frequent SNPs without any positive results, we conclude that the *KLF*15 and *KLF*16 genes are not likely to be associated with T2D in a French population.

A limitation of our study is the two-staged design, through which we may have missed a weak but true association with T2D. However, the use of T2D patients with affected first degree relatives and controls sharing the same environment as the cases in set 1, probably increased our power to detect an association with T2D. A second limitation of this study is the fact that it does not cover all the genetic variability of the *KLF*genes. However, our subsequent genome wide association analysis with 1,363 individuals also did not show significant T2D associations for variants of these genes, making it unlikely the nine KLFs play a major role in genetic T2D susceptibility.

We hypothesised that *KLF*genes could be associated with genetic susceptibility for T2D, based on their role in adipogenesis. In particularly, *KLF2*is implicated in the regulation of PPARγ \[[@B15]\], which is a target gene implicated in the genetic susceptibility for T2D. Therefore, we studied this gene more extensively and genotyped 9 SNPs. Also for *KLF*2 variants, we did not observe an association with T2D in this French population. In addition, a previous study of *KLF2*variants and body weight control in another French population did not observe an association with adipose tissue-related traits \[[@B22]\]. From these results, it seems unlikely that the genetic variability of the KLF2 gene plays a mayor role in susceptibility to T2D or obesity.

Conclusion
==========

In our study of variants from nine different members of the *KLF*gene family, we observed no association with T2D in our large French population. Moreover, the genotyped SNPs covered the overall genetic variability of the *KLF2*, -*1*5 and -*16*genes so we may conclude that these genes do not contribute to the genetic susceptibility of T2D.
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